Company intelligence / Profile preview

Artiva Biotherapeutics, Inc.

San Diego, California, United Statesartivabio.com ↗

Ownership: Public · ARTV
Development stage: Phase 1

Overview

AlloNK (AB-101) is being evaluated in clinical trials for autoimmune diseases and cancer. In NHL trials, it has demonstrated deep B-cell depletion and durable responses. The first patient with lupus nephritis was dosed in a Phase 1 trial in 2024. Initial data from the autoimmune program is expected in H1 2025, and updated NHL trial data will be presented at a medical conference in 2025[3][9].

Therapeutic areas: OncologyImmunology
Modalities: Natural killer (NK) cell-based therapiesCAR-NK cell therapies
Industry: Biotech

Drug pipeline

4 assets

Natural killer cell infusion

3 more assets in the full pipeline.

Request access →

Partnerships

Affimed N.V. (for AlloNK + AFM13 combination therapy)Lupus Therapeutics (for AlloNK development through Lupus Clinical Investigators Network sites)

Financials

Market cap: $509.4M
Total revenue: $0
Enterprise value: $169.9M

Beyond the preview

Go deeper on Artiva Biotherapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artiva Biotherapeutics, Inc..

Explore the full profile